Ernexa Therapeutics (ERNA) regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. On July 1, 2025, the company received formal notice from Nasdaq stating that Ernexa has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA:
- Ernexa Therapeutics expands Scientific Advisory Board
- Ernexa secures $6M in second closing under securities purchase agreement
- Eterna Therapeutics Implements 1-for-15 Reverse Stock Split
- Eterna Therapeutics trading halted, news pending
- Ernexa Therapeutics files to sell 57.05M shares of common stock for holders